Meeting
2020 ASCO Virtual Scientific Program
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
Authors
Jacob Sands
Lahey Hospital and Medical Center, Boston, MA
Jacob Sands , Sumithra J. Mandrekar , Geoffrey R. Oxnard , David E. Kozono , Shauna L Hillman , Suzanne Eleanor Dahlberg , Zhuoxin Sun , Jamie E. Chaft , Ramaswamy Govindan , David E. Gerber , Jhanelle Elaine Gray , Shakun M. Malik , Margaret M. Mooney , Pasi A. Janne , Everett E. Vokes , Karen Kelly , Suresh S. Ramalingam , Tom Stinchcombe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT02194738
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS9077)
DOI
10.1200/JCO.2020.38.15_suppl.TPS9077
Abstract #
TPS9077
Poster Bd #
270
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.
First Author: Jamie E. Chaft
First Author: Jamie E. Chaft
Poster
2023 ASCO Annual Meeting
Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.
First Author: Charu Aggarwal
Poster
2021 ASCO Quality Care Symposium
Biomarker testing patterns and actionability in advanced non-small cell lung cancer (aNSCLC) at OneOncology (OneOnc).
First Author: Ari M. Vanderwalde